Results 91 to 100 of about 8,927 (183)

Positive and Negative Cardiovascular Effects of JAK Inhibitors in Inflammation

ACR Open Rheumatology, Volume 8, Issue 6, June 2026.
Chronic inflammation, characteristic of many autoimmune diseases, such as rheumatoid arthritis (RA), or myeloproliferative neoplasms (MPNs), is an independent driver of accelerated cardiovascular (CV) risk, primarily through proinflammatory cytokines that induce atherosclerosis and endothelial dysfunction.
Aliki Zavoriti, Pierre Miossec
wiley   +1 more source

Psoriasis, Atopic Dermatitis, Acne, Inverse Psoriasis and Hidradenitis: A Case Report of Multiple Disease in a Same Young Patient

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT We report a case of a 17‐year‐old girl diagnosed with several severe dermatological conditions: atopic dermatitis (AD), inverse and scalp psoriasis, pustular acne, and hidradenitis suppurativa (HS). We consider this case of particular interest because it is therapeutically challenging and because of its psychological impact on the patient's ...
Emanuele Amore, Federica Trovato, Giovanni Pellacani, Annunziata Dattola, Antonio Giovanni Richetta   +4 more
wiley   +1 more source

Isoniazid‐Related Secondary Drug‐Induced Autoimmune Hepatitis in a Patient Diagnosed With Ankylosing Spondylitis and Tuberculous Lymphadenitis: A Case Report

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT Autoimmune hepatitis is a type of chronic hepatitis that is usually progressive, has unknown etiology, and can occur at any age. In the present case, drug‐associated autoimmune hepatitis (DIAIH) was discussed, and DIAIH secondary to isoniazid (INH) was found in two case reports in the literature.
Murat AY, Erhan Bozkurt
wiley   +1 more source

Real‐World, Prospective, Multicenter Outcomes to Brodalumab Treatment in Patients With Moderate‐to‐Severe Psoriasis in Greece (The RESOLVE Study)

JEADV Clinical Practice, Volume 5, Issue 2, Page 458-469, June 2026.
RESOLVE was a prospective, real‐world study in patients with moderate‐to‐severe psoriasis treated with brodalumab. At Week 12, 76.4% achieved PASI ≤ 3, 53.5% PASI100, and 71.5%/54.2% achieved sPGA0/1 and sPGA 0, respectively. At Week 52, 96.1% achieved sPGA success (clear/almost clear). Furthermore, at Week 52, mean DLQI scores decreased by 12.6 ± 6.2,
Electra Nicolaidou, Pantelis Panagakis, Dimitrios Xekardakis, Natalia Rompoti, Marina Papoutsaki, Ioanna Lefaki, Kanella Kalapothakou, Despina Exadactylou, Athanasios Chaniotis, Vasiliki Chasapi, Alexander Stratigos   +10 more
wiley   +1 more source

Effect of Systemic Immunomodulators on Incidence of Alopecia Areata: A Retrospective Cohort Study

JEADV Clinical Practice, Volume 5, Issue 2, Page 593-596, June 2026.
ABSTRACT Background Alopecia areata (AA) is a chronic autoimmune hair loss disorder. Patients with primary autoimmune diseases commonly use systemic immunomodulators to manage disease and have an increased risk of developing AA. Systemic immunomodulators have diverse immunologic effects, but their impact on AA risk is not well understood. Objectives We
Angela Rose Liu, Nada Hentati, Bethany R. Rohr   +2 more
wiley   +1 more source

Characteristics and Clinical Outcomes of Patients With Hidradenitis Suppurativa (HS) Treated With Bimekizumab: A Canadian Retrospective Chart Review

JEADV Clinical Practice, Volume 5, Issue 2, Page 627-631, June 2026.
ABSTRACT Background Hidradenitis suppurativa (HS) is a chronic, recurrent inflammatory skin disease characterised by painful nodules, abscesses, and draining and non‐draining tunnels. Currently, there are two biologics approved in Canada for the treatment of moderate‐to‐severe HS, adalimumab (anti‐TNF) and secukinumab (anti‐IL‐17A).
Irina Turchin, Tracey Brown‐Maher, Hélène Veillette, David O. Croitoru, Kyle Cullingham   +4 more
wiley   +1 more source

New Biologic and Small Molecule Therapies for Hidradenitis Suppurativa

JEADV Clinical Practice, Volume 5, Issue 2, Page 373-384, June 2026.
ABSTRACT Hidradenitis suppurativa (HS) is an inflammatory skin disease that has historically been underdiagnosed and, until recently, under‐researched. Furthermore, the pathophysiology of HS is complex, and not fully understood. Just three biologic medications—adalimumab (anti‐TNF‐α), secukinumab (anti‐IL17A) and bimekizumab (anti‐IL17A/F) are licensed
Emily Pender, Rosalind Hughes, Brian Kirby   +2 more
wiley   +1 more source

Artificial Intelligence Versus Conventional Scoring for Assessing Small Bowel Capsule Endoscopy Cleanliness in Crohn's Disease

United European Gastroenterology Journal, Volume 14, Issue 5, June 2026.
ABSTRACT Background and Aims Evaluation of cleanliness in capsule endoscopy is essential to validate the exam. However, reliable evaluation of bowel cleanliness remains challenging. The validated KODA score provides robust assessment but is time‐consuming and impractical in routine practice.
Raphaëlle Rouveyre, Catherine Le Berre, Romain Leenhardt, Michael Collins, Astrid De Massin, Mathurin Flamant, Caroline Trang‐Poisson, Guillaume Bouguen, Nina Dib, Aymeric Histace, Theo Soude, Xavier Dray, Arnaud Bourreille   +12 more
wiley   +1 more source

Association of Body Mass Index with SARS‐CoV‐2 Infection in Inflammatory Arthritis Patients Receiving Biologic Therapy: Singapore National Biologics Register Findings

International Journal of Rheumatic Diseases, Volume 29, Issue 6, June 2026.
ABSTRACT Purpose To determine the association of body mass index (BMI) with incident COVID‐19 infection in patients with inflammatory arthritis (IA) using biologic disease‐modifying anti‐rheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs) and to describe characteristics of patients with severe COVID‐19 infection. Methods This prospective
Preeti Dhanasekaran, Siaw Ing Yeo, Yi Xin Ng, Rosa Lim, Stephanie Wong, Stanley Angkodjojo, Andrew Yu Keat Khor, Li Wearn Koh, Manjari Lahiri, Margaret Ma   +9 more
wiley   +1 more source

Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative

ClinicoEconomics and Outcomes Research, 2018
Giorgio L Colombo,1,2 Sergio Di Matteo,2 Chiara Martinotti,2 Steffen M Jugl,3 Praveen Gunda,4 Mariantonietta Naclerio,5 Giacomo M Bruno2 1Department of Drug Science, Pavia University, Pavia, Italy; 2S.A.V.E. S.r.l.
Colombo GL, Di Matteo S, Martinotti C, Jugl SM, Gunda P, Naclerio M, Bruno GM   +6 more
doaj